The Food and Drug Administration (FDA) is considering lifting restrictions on certain peptide injections that are currently restricted due to safety concerns. The agency will convene a meeting with an outside advisory panel in July to discuss whether to allow compounding pharmacies to manufacture peptides for ulcerative colitis, wound healing, obesity, and more. This follows pledges by Health Secretary Robert F. Kennedy Jr. to reduce regulatory bureaucracy over peptides and make them more accessible. The meeting will consider removing seven peptides, including BPC-157, TB-500 and five others, which are currently banned by the World Anti-Doping Agency for use by athletes.